Document Detail


Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-II.
MedLine Citation:
PMID:  19791425     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dr. O'Connor delivered the following material as a poster at the 2003 American Society of Hematology meeting highlighting results from his work with bortezomib in the treatment of non-Hodgkin's and mantle cell lymphoma. A full publication of his results will appear later this year. Abstract #2346 appears in Blood, Volume 102, issue 11, November 16, 2003. The American Society of Hematology Poster Session "Lymphoma: Treatment and Supportive Care" took place on Sunday, December 7, 2003.
Authors:
Owen O'Connor; John Wright; Craig H Moskowitz; Jamie Muzzy; Barbara MacGregor-Cortelli; Paul Hamlin; David Straus; Elizabeth Trehu; David P Schenkein; Andrew D Zelenetz
Related Documents :
20448525 - Recent advances in the treatment of t-cell lymphomas.
20198395 - Highlights from the scientific and educational abstracts presented at the aser 2009 ann...
17776465 - Scientific meetings.
21688705 - Ontario: prostitution-related provisions of criminal code struck down.
21702745 - In all questions, my interest is not in the individual people but in the analytic movem...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the National Comprehensive Cancer Network : JNCCN     Volume:  2 Suppl 4     ISSN:  1540-1405     ISO Abbreviation:  J Natl Compr Canc Netw     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2009-10-01     Completed Date:  2009-10-14     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101162515     Medline TA:  J Natl Compr Canc Netw     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S21-2     Citation Subset:  IM    
Affiliation:
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Boronic Acids / therapeutic use*
Humans
Lymphoma, Mantle-Cell / drug therapy*
Lymphoma, Non-Hodgkin / drug therapy*
Protease Inhibitors / therapeutic use*
Proteasome Endopeptidase Complex / antagonists & inhibitors*
Pyrazines / therapeutic use*
Chemical
Reg. No./Substance:
0/Boronic Acids; 0/Protease Inhibitors; 0/Pyrazines; 0/bortezomib; EC 3.4.25.1/Proteasome Endopeptidase Complex

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Bortezomib in combination with other therapies for the treatment of multiple myeloma.
Next Document:  Intraoperative administration of low-molecular-weight heparins in reconstructive vascular operations